Calluna Pharma
Manufacturing · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gaustadalléen 21, Oslo, Oslo, 0349, Norw...Website
www.callunapharma.comRevenue
<$5 MillionIndustry
About Calluna Pharma
Calluna Pharma Org Chart
Is Calluna Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Calluna Pharma has new funding data
Product Launch: Get notified when Calluna Pharma launches new products
Click to see if Calluna Pharma had a recent Job posting/layoffs
Check if Calluna Pharma has recently received funding, and reach out quickly before it becomes old news!
Calluna Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Calluna Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Calluna Pharma
Earning: See what the market has to say on Calluna Pharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Calluna Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Calluna Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Calluna Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Calluna Pharma.
Calluna Pharma financials insights
Gather financial insights about Calluna Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$81.4M
Calluna Pharma Tech Stack
Most Recent Scoops
Calluna Pharma News & Media
Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications
OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate. The study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile for the mAb. CAL101 is a first-in-class mAb that targets S100A4, a damage-associated molecular pattern (DAMP) protein implicCalluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark ... - Cambridge Network
Executive appointments will drive growth strategy and progression of clinical pipelineCalluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board
OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board. Alongside these appointments, John Montana, who has been acting as the Company's interim CEO, will return to his role as an Operating Partner at Forbion. Gaffney brings over 20 years of experi
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Calluna Pharma
Based in Oslo, Norway, Calluna Pharma is a pharmaceutical company with a focus on immunological diseases.... Read More